The relative value of CD4 cell count and quantitative HIV-1 RNA in predicting survival in HIV-1-infected women: Results of the women's interagency HIV study

AIDS

Volumn 13, Issue 13, 1999, Pages 1717-1726

  Anastos, Kathryn ^a,l   Kalish, Leslie A ^b   Hessol, Nancy ^c   Weiser, Barbara ^d   Melnick, Sandra ^m   Burns, David ^e   Delapenha, Robert ^f   DeHovitz, Jack ^g   Cohen, Mardge ^h   Meyer, William ⁱ   Bremer, James ^j   Kovacs, Andrea ^k  

^a MONTEFIORE MEDICAL CENTER   (United States)

^b NEW ENGLAND RESEARCH INSTITUTES   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d WADSWORTH CENTER   (United States)

^e EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^f HOWARD UNIVERSITY COLLEGE OF MEDICINE   (United States)

^g SUNY DOWNSTATE MEDICAL CENTER   (United States)

^h MA   (United States)

ⁱ QUEST DIAGNOSTICS NICHOLS INSTITUTE   (United States)

^j RUSH MEDICAL COLLEGE   (United States)

^k UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^l ST VINCENT S HOSPITAL   (United States)

^m NONE

more..

Author keywords

CD4 cell count; HIV; HIV 1 RNA; Survival; Women

Indexed keywords

CD4 ANTIGEN; VIRUS RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; SURVIVAL;

CD4 LYMPHOCYTE COUNT; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HIV-1; HUMANS; MULTIVARIATE ANALYSIS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RNA, VIRAL; SURVIVAL RATE;

EID: 0033375084     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199909100-00016     Document Type: Article

References (41)

1. Mellors J, Rinaldo C, Gupta P, White R, Todd J, Kingsley L. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996, 272:1167-1170.
2. Mellors JW, Munoz A, Giorgi JV, et al. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997, 126:946-954.
3. O'Brien WA, Hartigan PM, Martin D, and the Veterans Affairs Cooperative Study Group on AIDS. Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. New Engl J Med 1996, 334:426-431.
4. Polk BF, Fox R, Brookmeyer R, et al. Predictors of the acquired immunodeficiency syndrome developing in a cohort of seropositive homosexual men. New Engl J Med 1987, 316:61-66.
5. Fahey JL, Taylor JMG, Detels R, et al. The prognostic value of cellular and serologic markers in infection with human immunodeficiency virus type 1. New Engl J Med 1990, 322:166-172.
6. Lemp GT, Payne S, Neal D, Temelso T, Rutherford RW. Survival trends for patients with AIDS. JAMA 1990, 263:402-406.
7. Chaisson R, Keruly J, Moore R. Race, sex, drugs use, and progression of human immunodeficiency virus disease. New Engl J Med 1995, 333:751-756.
8. Enger C, Graham N, Peng Y, et al. Survival from early, intermediate, and late stages of HIV infection. JAMA 1996, 275:1329-1334.
9. Whyte BC, Swanson C, Cooper D. Survival of patients with the acquired immunodeficiency virus in Australia. Med J Aust 1987, 150:358-362.
10. Hughes, MD, Johnson VA, Hirsch MS, et al. for the ACTG 241 Protocol Virology Substudy Team. Monitoring plasma HIV-1 RNA levels in addition to CD4 lymphocyte count improves assessment of antiretroviral therapeutic response. Ann Intern Med 1997, 126:929-937.
11. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. New Engl J Med 1997, 337:725-733.
12. Mellors JW, Kingsley LA, Rinaldo CR, et al. Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. Ann Intern Med 1995, 122:573-579.
13. Katzenstein DA, Hammer SM, Hughes MD, et al. for the AIDS Clinical Trials Group Study 175 Virology Study Team. The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. New Engl J Med 1996, 335:1091-1098.
14. O'Brien WA, Hartigan PM, Daar FS, et al. for the VA Cooperative Study Group on AIDS. Changes in plasma HIV RNA levels and CD4+ lymphocyte counts predict both response to antiretroviral therapy and therapeutic failure. Ann Intern Med 1997, 126:939-945.
15. Delta Coordinating Committee. Delta: a randomized double-blind controlled trial comparing of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Lancet 1996, 348:283-291.
16. Brun-Vezinet F, Boucher C, Loveday C, et al. HIV-1 viral load, phenotype, and resistance in a subset of drug-naïve participants from the Delta trial. Lancet 1997, 350:983-990.
17. Fang G, Siegal FP, Weiser B, et al. Measurement of human immunodeficiency virus (HIV) type 1 RNA load distinguishes progressive infection from nonprogressive HIV-1 infection in men and women. Clin Infect Dis 1997, 25:332-333.
18. Vlahov D, Graham N, Hoover D, et al. Prognostic indicators for AIDS and infectious disease death in HIV-infected injection drug users. JAMA 1998; 279:35-40.
19. Jacobson L, Wolinsky S, Detels R, et al. HIV-1 viral burden predicts survival among severely immunosuppressed HIV-1 infected men. Fifth Conference on Retroviruses and Opportunistic Illnesses. Chicago, February 1998 [abstract 208].
20. Cozzi Lepri A, Katzenstein TL, Ullum H, et al. The relative prognostic value of plasma HIV RNA levels and CD4 lymphocyte counts in advanced HIV infection. AIDS 1998, 12:1639-1643.
21. De Wolf F, Spijkerman IJB, Schellekens P, et al. AIDS prognosis based on HIV-1 RNA, CD4+ T-cell count and function: markers with reciprocal predictive value over time after seroconversion. AIDS 1997, 11:1799-1806.
22. Evans JS, Nims R, Cooley J, et al. Serum levels of virus burden in early-stage human immunodeficiency virus type 1 disease in women. J Infect Dis 1997, 175:795-800.
23. Brabazon C, Logue K, Burchell A, Galli R. Gender differences in antiretroviral therapy received in ontario: a possible effect of viral load differences. XII International Conference on AIDS. Geneva, July 1998 [abstract 42145].
24. Farzadegan H, Hoover D, Astemborski A, et al. Sex differences in HIV-1 viral load and progression to AIDS. 1998, Lancet 352:1510-1514.
25. Lyles C, Vlahov D, Farzadegan H, et al. Comparisons of two measures of human immunodeficiency virus (HIV) type 1 load in HIV risk groups. J Clin Microbiol 1998, 36:3647-3652.
26. Junghans C, Ledergerber B, Chan P, Weber R, Egger M, for the Swiss HIV Cohort Study. Sex differences in HIV-1 viral load and progression to AIDS [letter]. Lancet 1999, 353:589.
27. Moroni M. Sex differences in HIV-1 viral load and progression to AIDS. ICONA Study Group. Italian cohort of HIV-1 positive individuals [letter]. Lancet 1999, 353:591.
28. Bush C, Donovan R, Markowitz N, Baxa D, Kvale P, Saravolatz L. Gender is not a factor in serum human immunodeficiency virus type 1 RNA levels in patients with viremia. J Clin Microbiol 1996, 34:970-972.
29. Moore R, Cheever L, Keruly J, Chaisson R. Lack of sex difference in CD4 To HIV-1 RNA viral load ratio [letter]. Lancet 1999, 353:463-464.
30. Maini M, Gilson R, Chavada N, et al. Reference ranges and sources of variability of CD4 counts in HIV-seronegative women and men. Genitourin Med 1996, 72:27-31.
31. Tollerud DJ, Clark JW, Morris Brown L, et al. The influence of age, race, and gender on peripheral blood mononuclear-cell subsets in healthy nonsmokers. J Clin Immunol 1989; 9:214-222.
32. Barkan SE, Melnick SL, Preston-Martin S, et al. The Women's Interagency HIV Study (WIHS) - design, methods, sample, cohort characteristics and comparison with reported AIDS cases in U.S. women. Epidemiology 1998; 9:117-125.
33. Kaplan EL, Meier P. Nonparamatric estimation from incomplete observation. J Am Statist Assoc 1958; 53:478-481.
34. Green PJ, Silverman BW. Nonparametric Regression and Generalized linear Models. London: Chapman and Hall; 1994.
35. Sleeper IA, Harrington DP. Regression splines in the Cox model with application to covariate effects in liver disease. J Am Statist Assoc 1990, 85:941-949.
36. Anastos K, Gange S, Lau B, et al. Gender differences in virologic and immunologic markers of HIV-1 disease. Sixth Conference on Retroviruses and Opportunistic Infections. Chicago, January February 1999 [abstract 274].
37. Burleson M, Malarkey W, Cacioppo J, et al. Postmenopausal hormone replacement: effects on autonomic, neuroendocrine and immune reactivity to brief psychological stressors. Psychosom Med 1998, 60:17-25.
38. Delmas M-C, Jadand C, De Vincenzi I, et al. and the SEROCO Study Group. Gender difference in CD4+ cell counts persist after HIV-1 infection [letter]. AIDS 1997, 11:1071-1073.
39. Vandamme AM, Schnit JC, Van Dooren S, et al. Quantification of HIV-1 RNA in plasma: comparable results with the NASBA HIV-1 RNA QT and the Amplicor HIV Monitor Test. J Acquir Immune Defic Syndr Hum Retrovirol 1996, 1:13(2) 127-139.
40. Dyer J, Pilcher C, Shepard R, Schock J, Eron JJ, Fiscus SA. Comparison of NucliSens and Roche Monitor assays for HIV-1 RNA quantitation. Twelfth World AIDS Conference. Geneva, June-July 1998 [abstract 42162].
41. Weiser B. Molecular determinants of HIV disease progression in drug-using women. Preconference Symposium on Current Concepts of HIV Pathogenesis in Women. Geneva, June 1998.